Ark strengthens wound care range with Kerraped
UK-based wound care specialist Ark Therapeutics' Patient Plus subsidiary has signed an exclusive licensing agreement with Germany's Darco GmbH, which grants the former rights to a medical footware device developed by the latter. The product, which is designed to treat patients with diabetic foot ulcers, will be marketed under the brand name Kerraped in both the UK and certain international markets.
Under the terms of the deal, financial details of which were not made public, Darco will manufacture and supply the product to Ark for an agreed price. In return, the UK firm will be responsible for reimbursment and conducting all sales and marketing activities.
Ark said that, having gained price reimbursement for use in the UK National Health Service, it plans to launch an all-purpose boot- and a light-weight shoe-version of the product in August this year, which will retail at L16.63 ($32.67) and L12.57, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze